<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04899466</url>
  </required_header>
  <id_info>
    <org_study_id>RD008</org_study_id>
    <nct_id>NCT04899466</nct_id>
  </id_info>
  <brief_title>Efficacy Evaluation of ActiGraft in Secondary Closure of Abdominal Surgical Wound Dehiscence</brief_title>
  <official_title>A Prospective Study Evaluating the Efficacy of ActiGraft in Secondary Closure of Abdominal Surgical Wound Dehiscence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RedDress Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RedDress Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, single arm study, consisting of 20 women with abdominal surgical wound&#xD;
      dehiscence that requires secondary closure. The participants will receive a weekly&#xD;
      application of ActiGraft for 4 weeks, or until complete healing of the wound (the earlier of&#xD;
      the two).&#xD;
&#xD;
      An historic matched-control group of 20 patients will be compared retrospectively&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of complete wound closure</measure>
    <time_frame>4 weeks</time_frame>
    <description>Skin re-epithelialization without drainage or dressing requirements</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Wound Percent Area Reduction (PAR)</measure>
    <time_frame>2, 4 and 6 weeks</time_frame>
    <description>The change in wound area (decrease or increase) with respect to the area at baseline, expressed as a percentage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time of complete wound closure</measure>
    <time_frame>4 weeks</time_frame>
    <description>Skin re-epithelialization without drainage or dressing requirements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Durability of wound closure 2 weeks after complete healing</measure>
    <time_frame>Up to 6 weeks</time_frame>
    <description>No wound dehiscence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of time to complete closure between study cases and historic control</measure>
    <time_frame>4 weeks</time_frame>
    <description>Skin re-epithelialization without drainage or dressing requirements</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in pain level</measure>
    <time_frame>1, 2, 3 and 4 weeks</time_frame>
    <description>Measured by Numeric Rating Scale (0 - no pain at all to 10 - worst pain) weekly for 4 weeks post ActiGraft application</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>1, 2, 3, 4, 6 weeks and 42 days</time_frame>
    <description>Will be assessed by subject satisfaction survey using a 5-point Likert Scale (the higher score means a better outcome).</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Dehiscence Wound</condition>
  <arm_group>
    <arm_group_label>ActiGraft</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Whole blood clot (WBC) gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ActiGraft</intervention_name>
    <description>Whole blood clot (WBC) gel</description>
    <arm_group_label>ActiGraft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt;18 years&#xD;
&#xD;
          -  Women that had a laparotomy no more than 3 weeks before accrual.&#xD;
&#xD;
          -  Surgical wound dehiscence that requires a secondary closure.&#xD;
&#xD;
          -  Time from wound dehiscence &gt;24 hours and &lt;6 days.&#xD;
&#xD;
          -  The open wound includes epidermis, dermis and sub cutaneous fat.&#xD;
&#xD;
          -  The patient can sign an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with necrotizing fasciitis&#xD;
&#xD;
          -  Patients with fascial dehiscence&#xD;
&#xD;
          -  Cannot withdraw blood in the required amount (up to 18 mL per week).&#xD;
&#xD;
          -  Known coagulation problems, abnormal thrombocytes level or if heparin is given&#xD;
             intravenously. Subjects who are taking oral anti-coagulants or anti-agreganrts will&#xD;
             not be excluded.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Subject is currently receiving (i.e., within the past 30 days) or scheduled to receive&#xD;
             systemic steroids (Prednisone- more than 10mg/d or equivalent).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon Sirota</last_name>
    <role>Study Director</role>
    <affiliation>RedDress Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharon Sirota</last_name>
    <phone>+972545800765</phone>
    <email>sharon@reddress.co.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Emek Medical Center</name>
      <address>
        <city>Afula</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Yifat Kadan, Dr. Med.</last_name>
      <phone>+972506943426</phone>
      <email>yfat_ka@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Yifat Kadan, Dr. Med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2021</study_first_posted>
  <last_update_submitted>May 23, 2021</last_update_submitted>
  <last_update_submitted_qc>May 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Dehiscence</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Surgical Wound</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The results will be part of several scientific publications</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Upon publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

